Itolizumab in Psoriasis

A number of biologics is being used for the treatment of psoriasis. Itolizumab is one such agent which has been approved in India. It is an anti-CD6 monoclonal antibody that acts by binding to scavenger receptor cysteine-rich (SRCR) distal domain 1 of CD6. Itolizumab has been found to be safe, with...

Descripción completa

Detalles Bibliográficos
Autor principal: Srivastava, Ankita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2017
Materias:
Resident's Page
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5527725/
https://www.ncbi.nlm.nih.gov/pubmed/28794555
http://dx.doi.org/10.4103/ijd.IJD_467_16
_version_ 1783252978710347776
author Srivastava, Ankita
author_facet Srivastava, Ankita
author_sort Srivastava, Ankita
collection PubMed
description A number of biologics is being used for the treatment of psoriasis. Itolizumab is one such agent which has been approved in India. It is an anti-CD6 monoclonal antibody that acts by binding to scavenger receptor cysteine-rich (SRCR) distal domain 1 of CD6. Itolizumab has been found to be safe, with infusion reactions as the most common adverse effect. However, its advantages and disadvantages over other biologicals and immunosuppressants need to be established. Also, its utility in treating other immune-mediated disorders is being explored.
format Online
Article
Text
id pubmed-5527725
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-55277252017-08-09 Itolizumab in Psoriasis Srivastava, Ankita Indian J Dermatol Resident's Page A number of biologics is being used for the treatment of psoriasis. Itolizumab is one such agent which has been approved in India. It is an anti-CD6 monoclonal antibody that acts by binding to scavenger receptor cysteine-rich (SRCR) distal domain 1 of CD6. Itolizumab has been found to be safe, with infusion reactions as the most common adverse effect. However, its advantages and disadvantages over other biologicals and immunosuppressants need to be established. Also, its utility in treating other immune-mediated disorders is being explored. Medknow Publications & Media Pvt Ltd 2017 /pmc/articles/PMC5527725/ /pubmed/28794555 http://dx.doi.org/10.4103/ijd.IJD_467_16 Text en Copyright: © 2017 Indian Journal of Dermatology http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
spellingShingle Resident's Page
Srivastava, Ankita
Itolizumab in Psoriasis
title Itolizumab in Psoriasis
title_full Itolizumab in Psoriasis
title_fullStr Itolizumab in Psoriasis
title_full_unstemmed Itolizumab in Psoriasis
title_short Itolizumab in Psoriasis
title_sort itolizumab in psoriasis
topic Resident's Page
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5527725/
https://www.ncbi.nlm.nih.gov/pubmed/28794555
http://dx.doi.org/10.4103/ijd.IJD_467_16
work_keys_str_mv AT srivastavaankita itolizumabinpsoriasis

Ejemplares similares